Close Menu

This article has been updated with additional information from Myriad Genetics' earnings call.

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its second quarter revenues in fiscal 2018 dipped 1 percent, largely due to a 12 percent decline in hereditary cancer testing revenues, which dragged down its total molecular diagnostic testing sales.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.